Exchange: NYSEMkt·Updated 07:30 PM EST
MAIA logo

MAIA MAIA Biotechnology Inc

$1.14
$0.03
(2.63%)
Today
Closed $1.11
$0.03
(2.70%)
After Hours
Reported EarningsAug 5
Mkt Cap$68.54M
Vol508,769.00

About MAIA

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.
81

Extremely Bullish Sentiment

How do you feel about MAIA?

Jacko27
$MAIA Been digging into the company’s trial and market a lot and the setup looks better the deeper I go. As a long term investor, I personally do not care what the share price looks like in the short term. I add every week, whether it’s higher or lower. It doesn’t sit in the bigger picture. I am strictly going to give my thoughts on the data/trial and the companies market. To me, everything else is moot and a red herring. The basics on (THIO104) - a P3 3L trial, so two prior lines including immunotherapy and platinum chemo, and patients need acquired resistance to their prior checkpoint inhibitor, meaning primary non responders are out. The control arm is investigators choice of docetaxel, gemcitabine, or vinorelbine, but docetaxel is only allowed if the patient hasnt had it, and most 3L patients already got it in 2L. The bulk control is mostly the weaker agents, which I’d pin at 75%. Supporting literature and specifically ATALANTE1, which had a similar acquired resistance population on docetaxel or pemetrexed, came in at 7.5 months, real world post IO taxane data is around 7.3, and 3L vinorelbine after IO lands around 6.5 to 8. Ive got the control group around 7.3 months. On our side, THIO101 showed a 17.8 mOS in 3L with a 5.6-month PFS, and that was in a population that included primary non responders and some fourth line patients, so arguably tougher than THIO104. The 8 patients on the Phase 3 dose had a 5.5-month PFS with 75% alive at 6 months (stack some curves/napkin math on that gets you a 15 mOS), and Part C put up a replicated 90.5% disease control rate in an all docetaxel exposed group. When most patients arent progressing early and PFS is roughly double what the vinorelbine and gemcitabine patients typically get, fewer people drop off treatment early, more stay on long enough for the immune priming to actually work, and you get less premature dropout with cleaner survival data. Crossover shouldnt be much of a worry. THIO isnt available outside of trials, sponsors running an OS trial with an unapproved drug rarely allow control patients to switch over, and after failing 3L chemo there are very few effective options left, so the control arms survival shouldnt get inflated by later treatments the way it did in some earlier NSCLC trials. The mechanism will certainly help our arm with the curve shape too. THIO hits telomeres and kills cancer cells within days, then the checkpoint inhibitor comes in on primed immune cells. Fast direct kill should separate the curves early, which is what you want with a 131 event interim, and the immune piece should drive a long term survival tail for the final. Very bullish for interim and FA. With the chemo arm progressing around the 3 month mark, Id expect separation early rather than late, which is what shapes the true HR in an unweighted log rank cox HR SAP (very likely). My estimate is 14 to 17 months for the THIO arm vs about 7-8 for control, so an HR around .50 depending on survival curves, and the trial would have to fall to roughly 9.5 months before it actually misses stat sig. Lots of cushion there. The margin of safety is massive. Between the tiny 70m market cap, weak control arm, the acquired resistance enrichment, replicated disease control, and steady insider buying, I like the risk/reward a lot here. Contingent on the upcoming Phase 2C data we receive in the coming months, I’d assign an 83% chance we meet statistical significance at final analysis. On the 3L market, expansion, and Telomerase positive cancer types - Let’s start with the base case MAIA is building toward. Some people on here say the # isn’t 50k, while others stand behind it and claim it is. For now, I’m going to go off of MAIA’s investor deck slides and what they’ve put in front is us. You can adjust the math accordingly based on what you think the true addressable population is. At MAIA’s claimed 50,000 US addressable patients a year who are resistant to CI’s/chemo agents and $150,000 per patient, the theoretical 3L US market is $7.5 billion annually. As there are no approved therapies or SOC in 3L, penetration will run high if the spread sheets look good. At a hypothetical 50% share, thats roughly 3.7b in peak sales. At 65%, which is relatively plausible here for an OS winner against single agent chemo with nothing better, it’s about $4.8b. The precedent is that the FDA grants labeling flexibility in a market with no SOC/high unmet need, so the 50-65% penetration is very realistic, especially with a .50 HR. I temper my expectations to 45-50%, although the 65-70% is certainly a possibility if stars align, which is rare but possible in biotech. The margin profile is strong. THIO is a small molecule nucleoside analog, a modified version of a DNA building block made through standard chemical synthesis, so it doesnt need the expensive living cell manufacturing that antibodies and ADCs require. Its also given at low doses for only three days per 21 day cycle, so the amount of drug per patient is tiny relative to a price around $150,000, which pushes the cost of goods down to roughly 1% of revenue. At 1% COGS, gross margin is essentially 99%. Even if the real number lands at 3-5%, which is more typical for a small molecule, it’s still exceptionally high. The cemiplimab component is billed separately by Regeneron, so THIO keeps its own economics. The real costs are commercial, being a US oncology launch runs a few hundred million dollars a year in sales force, medical affairs, and market access. At 4b in sales, operating margins of 65% are realistic, which is exactly why big pharma would rather buy this than compete with it. Once again, if you disagree, tailor your expectations accordingly based on what you believe the margins and pricing are. Second line is where the market roughly doubles. Most 1L patients now get chemo and immunotherapy together, so when they progress they already have the same resistance profile THIO104 is enrolling, just one line earlier. Some 2L use could come quickly through label wording or NCCN guideline listing, but a broad 2L label would need a confirmatory trial. Docetaxel only control makes for a tougher comparator than THIO104 faces, with a control median of 10-12 months instead of about 7. If THIO104 hits with an HR around 0.5, Id put the odds of a successful 2L trial at roughly 70%. The effect would likely shrink against a stronger control with biology carrying over. A lucky 2L label could add another 1b in peak US sales, while an AA could win another $1-3 billion in peak sales on top of that, since patients would be on therapy longer. Then theres the a bigger piece we’re all invested for - the telomerase story. Roughly 85% of cancers reactivate telomerase, which is the theoretical ceiling for the platform. The near term pieces are the investigator run HCC trial at UT Southwestern, testing THIO plus cadonilimab against cadonilimab alone before surgery, and MAIAs preclinical work in other telo positive cancer types, including second generation telomere targeting molecules. Their real value is strategic. Each positive readout in another tumor type turns the 85% statistic from theory into evidence, and thats what moves an acquirer from paying for a single NSCLC drug to paying for a platform. If THIO104 seems a success, pharma will certainly price in the pan cancer optionality to a fair extent. I believe this story will end similar to Apogee and the company will be purchased after a P3 success. What number is that? I really don’t know. If I had to pin a certain scenario/number on a buyout, I’d assume a couple of bidders would be desperate for the TAM/optionality, and the price would land around 13b with a .5 HR. NFA. Conduct your own DD.
4
18
Jacko27
$MAIA Solid pooled DCR data. Half of that was the Part C cohort that scored a 90.5%. The 88% cited is between A, B, and C. I am still looking for what matters the most- an ORR, as that’s the primary endpoint and what supports an accelerated approval. Under standard response criteria, a response has to be confirmed on a follow up scan at least four weeks later. With Part C's last patients dosed in early October and first scans around week six, the full cohort's confirmed responses won't be complete until roughly December to January. There’s a chance we get it at the conference in January, although MAIA may want to wait for more mature durability, which could drag it to ASCO. Either way, it’s a score, and the company can raise into the headline. The company reiterated an expected interim for 2027, which is quite positive. They need to secure the stated 100 by year end to in line with that goal. The CEO and another board member buying 100k shares each reflects the consistent levels of confidence in the data and upcoming interim analysis. The future is looking bright. I’ll continue to add weekly.
21
Chemaster
$MAIA $SLS MAIA vs. SLS — 2026 open-market insider activity: MAIA: CEO and directors bought about $556K of shares on the open market. No open-market sales reported. SLS: No open-market insider buys or sells reported in 2026. MAIA insiders have been putting their own money into shares; SLS insiders have not made comparable open-market trades this year. FYI, I own both!
1
18
redfox43202
$MAIA The big pharma may want to acquire not only for the 3L market, but also move the sequential treatment to 1L. Thus big buck acquisition.
1
7
Chemaster
$MAIA For anyone new here! CEO Vlad Vitoc named the company after his daughter, Maia. That alone tells you this is personal, but his actions speak even louder. He and other insiders have invested millions of their own money, including open-market purchases as recently as last week, while never selling a single share. Vlad Vitoc, 1,398,821 shares Stan Smith, 1,632,918 shares Ramiro Guerrero, 773,296 shares This doesn’t look like a quick cash-flip deal. I believe Vlad is building something personal, something about legacy, for himself and for every shareholder who believed alongside him. THIO, with its cancer-specific targeting and the potential to affect approximately 85% of all cancers, may ultimately become a broad cancer-treatment platform, and legacy. Welcome here and good luck! IMO DYOR
2
8
Chemaster
$MAIA Read article on right side of Stocktwits page. NOTE: They skipped MAIA with NO stock sales by insiders ever and been stacking market purchased stocks for months!!!! $CAPR $IBRX $SLS $IOVA
14
MoneyHelix
$MAIA About 100k shares and counting 🥂 DCR is a good predictor of OS. Things are looking very promising for Phase 3 based off this data 🥂
11
telomerase
$MAIA No, Psycho, StockTwit posts are not predictive of stock prices 🤣 And there is no downward pressure on stock prices from small biotechs having shelf offerings available. They have to finance themselves somehow, and having a shelf available to use when there is good trial news is one of the least diluting ways. CADL would be less diluted now had it used its ATM instead of signing a below-market deal with some finance bros. Neither is the current drop indicative of anything but overall market revaluing. The only question here is how well ateganosine will do in Phase 3.
11
bullcall56
$MAIA 88% DCR (Disease Control Rate) in advanced third-line NSCLC patients (part C interim phase 2 trial). This DCR measure contrasts with reported 25%–35% disease control for standard 3L chemotherapy regimens. WOW! Hugely Impressive. A bit surprised the s/p isn't up sig. more.
1
7
MoneyHelix
$MAIA Just skimmed through the Q3 10Q. Here are some notes: 1) $6.3M cash burned in Q3. Fantastic cash control. 2) About $7.5M net loss, excluding the change in fair value of warrant liability. Fantastic cost control. 3) $0.9M of costs were paid for with stock-based compensation, conserving cash, but diluting by about 1M shares. 4) $21.3M of cash on the books. At this rate, we have 3 quarters of cash left on the books: Q4 2026, Q1 2027, and Q2 2027. The Phase 3 trial is reaching solid economic scale, creative cost efficiencies. I would be surprised if CEO Vitoc extends the cash runway all the way through Q3 2027 and into Q4 2027. He earned a lot of my trust in his cash management late 2025 and early 2026 when MAIA seemed like it was completely out of cash, only to be hit with a massive $33M injection. Hopefully this is enough to make it to the interim analysis, but we'll see 🥂
10
MoneyHelix
$MAIA fun price action! Could see another significant bump tomorrow! CEO Vitoc usually comes with a lot of good news at the end of the year. There will be more announcements to come leading into JPMHCC 2027
8
buyoutorbust_
$MAIA has covered the real world numbers of both experimental and control group survival estimations in THIO 104. He agrees 17.8 vs 5.8 is not reality, although 17.8 is a possibility in our arm. Just not his base case. He lands at a 14-15 mOS for Ateganosine (exp) and 7-7.5 mOS for the control therapies. With his estimations on what the survival curves will look like with his model, he estimates a .45-.58 HR; a very clear and strong win over the .75 HR bar to success. He has an 83% PoS for trial success. Good news is that it doesn’t need to be remotely close to either example listed to hit statistical significance. 17.8 vs 5.8 would be the best NSCLC trial result ever recorded by a long shot. Institutional backing is thin but growing. About 33-36 13F filers hold roughly $18M, up from 20 holders in mid 2025, and 16 opened or added positions last quarter vs 6 trimming. What's missing is specialist biotech funds, but that's mostly a size problem. at a $67M market cap with thin liquidity, they simply cannot build a solid position without moving the stock, and tutes usually wait until data is closer. Flip it around though, and the most informed buyers are already here. Insiders don't need 13Fs to due diligence because they see Part C in real time, an open label study where they're watching responses and survival come in months before the public does. The CEO owns roughly 10% of the company, and both the CEO and board have repeatedly bought shares on the open market while the company was actively raising capital and diluting. Insiders sell for a lot of reasons, but they only buy for one - they think the stock is going higher. Institutions will show up when the market cap lets them. The people with the best view of the data are buying now.
1
5
Hurricane76
$MAIA Eli Lilly inks cancer pact worth up to $5.9bn with Stipple Bio Stipple plans to initiate a Phase I trial for an ADC for solid tumours in early 2027
1
4
LittleBobbyAxelrod
$MAIA If someone picks them up after approval for 2L or even 1L this moves to blockbuster territory especially thay Keytruda patent expiring.
7
LabPsycho
$MAIA Here's some hope for MAIA longs...the lucky investors / pumpers from SLS with large % profits might be inclined to roll some of their profits into another phase 3 company - a lot of new posters here in the future might be one indication they are hoping for a round 2.
2
1
dragonbits
$MAIA Well, that bull run didn't last long 🥵. I have a ton of MAIA stock, there isn't any reason for me to be buying or selling atm. Maybe if it goes down more I will change my mind about that. Still here, still bullish, but not a great trading stock. ciao and arrivederci all.
6
bedazzled
$MAIA Trial results really look good. Should be nice catalyst for price. Don't really care since planning to hold for a while. I think end result will be worth the risk.
6
dragonbits
$MAIA Were you all buying below 1 and anyone get shares at 0.9599? My bottom fishing on Maia results. Set my first bait at 0.9900 and 0.998, just a bit below where most Maia shares were feeding. Sure enough, got bites at those levels, reeled in more shares. But remarkably, shares were still looking for liquidity, so bait at 0.9687, 0.9623, 0.9622, 0.9600. Little over 3k additional shares in the hopper. Had an order in at 0.9599, I see ~2500 at that price, but no joy for me. Next level is the Mariana Trench Hopefully this below $1 is over. Because … Being a bit OCD the power of the sale compels me, what is to be is to be done, mine is not to question why, only to do and not die.
1
3
Jacko27
$MAIA I disagree the TAM is only 14-20k 3L patients annually. Here are reasons why that number is too low. When an effective, well tolerated option appears in a later line such as our drug, Ateganosine, more patients will move and get treated there. 51.6% of patients starting first line reach 2L, which on 75K first line starts is roughly 39K patients. On the note of 1L-2L, that half of 51.6% comes from 2015-2021 data. Since then, first line chemo IO has extended survival, which means more patients live long enough to reach both 2L and 3L. One reason only about half of them go on to 3L is because the options are toxic chemo with poor results. If an approved drug with criteria I gave raises that 2L to 3L transition from 50% to a realistic 75%, you get about 30k patients reaching 3L. The follow up bias in these cohorts pushes it north of 32k only off of these two variables alone. Some who would have gone to hospice or supportive care after 2L progression get a 3L course instead. Some patients who progress but decline chemo due so because of toxicity, which is once again another reason why the 27% isnt going to be accurate. An approved, well tolerated drug with a strong survival benefit would recapture the majority of them. This is a historical cohort that describes an outdated funnel, not the one MAIA would launch into in 2028 ish. Another fact - the 27% statistic measures patients who actually received third line treatment, and it completely excludes patients who reached progression but never received another treatment due to the fact that chemo options are terrible, there is no SOC, and there’s no approved therapy for this specific population. On top of that, historical attrition combines mortality, deteriorating performance status, and decisions against additional treatment. A substantially better treatment will address the latter category, meaning observed utilization will underestimate future demand (2025 PMC study). This happens very frequently in other cancers as later line therapies improved. I’m not pinning a certain number to this as it’s more so subjective (but objectively true in the real world), but the number wouldn’t be 15-20k patients moving to 3L if our drug scores like I’ve said a realistic but unprecedented .50 HR with a 15 mOS and ultimately receives approval in this market with such a massive unmet need. Theres no direct literature to support an exact, precise increase in patients in an NSCLC specific population, so you need to read between the lines and stack realistic assumptions contingent on the success of THIO104. On the surface of 2L->3L, it’s obvious there is a bunch of white space that needs filling based on the unmet need. In NSCLC study cohorts, patients who entered late had limited follow up, and some hadn't reached 3L yet when data collection ended, even though they eventually would. Real world line of therapy rates tend to understate the true lifetime rate for that reason. Also, the real world base most people use undercounts annual first line starts. Stage IV at diagnosis is only part of the advanced population. A large share of patients diagnosed at earlier stages recur later and then start first line treatment for advanced disease. I believe your base only accounts patients who are advanced at diagnosis, you're leaving out the recurrence pool entirely, and every one of those patients is a potential 3L patient down the road. At the 180 mg Phase 3 dose, there were no drug related grade 4 events. Many 3L candidates are too frail for docetaxel or other chemo. A well tolerated option like Ateganosine expands the pool of patients oncologists are willing to treat, not just the share who choose to. I never included this but since you made a new post challenging my 3L population, NCCN matters here in 3L, not just 2L which is the only line I did include off label. Once a 3L drug shows a strong OS benefit on top of receiving approval, it gets listed in the guidelines, community oncologists start offering it instead of referring to hospice, and payers cover it. The 27% reflects a world of a subpopulation where 3L meant toxic chemo with single digit response rates. Adjust your calculations to a real world population outside of a narrower newly diagnosed only cohort, change what's available in 3L, and you change how many patients get there. These variables will simultaneously stack together and foster a true increase in the 3L market if Ateganosine receives approval. My own opinion will still likely be 35k patients who reach 3L annually and 28k ish who are THIO eligible after a 20% haircut after accounting for driver mutated patients and ineligible ECOG patients. My TAM relative to your number for the broader US 3L market is 150k (assumed) x 35k = 5.25B. My true, THIO eligible US 3L TAM (which is what you need to model) is 150k (assumed) x 28k = 4.2B
6
Ceasse
$MAIA I’m so bullish on this. Idk the way insiders have been buying is additional confirmation imo
5

Advertisement|Remove ads.